▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2515 by analyst upside · 2026-08-13
EWTX
Edgewise Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+17.4%
implied upside to consensus target
Current Price $43.56
Consensus Target $51.15
Bull Target $66.0
Bear Target $36.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
8
Hold
2
Sell
0
52-Week Low $13.38
52-Week High $48.4
YTD Return +83.4%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.85
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $13.38
52-Week High $48.4
Current Price $43.56
Bear Target $36.0
Bull Target $66.0
● Now $43.56 ● Target $51.15
TRADING DATA
Avg Volume 1.4M
YTD Return +83.4%
Analyst Count 13
Consensus Buy
Upside to Target +17.4%
Last Updated 2026-08-13

ANALYST SUMMARY

Edgewise Therapeutics, Inc. (EWTX) is currently trading at $43.56 with a Wall Street consensus price target of $51.15, implying potential upside of 17.4% over the next 12 months. 13 analysts currently cover EWTX, with a consensus rating of Buy - 85% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $66.0, while the most cautious has a target of $36.0.

EWTX operates in the Healthcare sector with a market capitalisation of $5B. The stock is up 83.4% year-to-date and is currently trading near the upper end of its 52-week range of $13.38 – $48.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ACAD +13.8%
ACADIA Pharmaceuticals Inc.
$5B · P/E 13.2x · Buy
INDV +26.5%
Indivior Pharmaceuticals, Inc.
$5B · P/E 13.9x · Buy
GRFS +37.0%
Grifols, S.A.
$5B · P/E 10.4x · Buy
CAI +21.3%
Caris Life Sciences, Inc.
$6B · P/E 2.3x · Buy
CON +11.8%
Concentra Group Holdings Parent, Inc.
$4B · P/E 21.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for EWTX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital - Reiterated
Outperform → Outperform 2026-06-17 Building track record
Goldman Sachs - Reiterated
Neutral → Neutral 2026-06-17 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-06-16 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-06-02 31% win rate (48 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-06-02 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-06-02 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-03-17 43% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-03-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
58
out of 100
Coverage depth
20/30
Consensus clarity
16/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →